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Effect of Telomerase Inhibitors on Malignant Breast Cancer Cells
Alexander J. Fisch, Osman V. Patel
Department of Cell and Molecular Biology, Grand Valley State University, Allendale, MI 49401

Abstract
Current therapies have nominal effect on the most intrusive-type of breast cancers (triplenegative) that have a higher tendency to metastasize or recur. Recent studies reveal an enzyme,
telomerase, as key for unlimited cell growth (immortality) and replication. Therefore, our
objectives were to assess (i) short- and (ii) long-term effects of a novel anti-telomerase agent
(GV6) developed at our institute and compare it to a known analogue, BIBR1532 on MDA-MB
231 breast cancer cells. Cell viability was measured on days 5, 9, 14, 18 and 27 after treatment
with GV6 (n=4), BIBR1532 (n=4) or Solvent alone (Control, n=3). The number of viable cells in
GV6 and BIBR1532 treated flasks (T75) were about 40% (p<.05) of Control by day 14. It further
dropped to 30% (p<.05) of Control by day 27 for both, GV6 and BIBR1532. Our results indicate
the anti-proliferative effect of GV6 parallels that of BIBR1532 and should be investigated
further.

Introduction
During 2013 alone, we estimate about 1,700,000 new cases of cancer to be diagnosed in
the United States, leading to almost 1,600 deaths per day. Of the new cases, about 240,000 will
be attributed to breast cancers diagnosed among women bringing with it a fatality rate of
approximately 40,000 from this disease (1), making it one of the most deadly cancers. There are
three key receptors that are commonly known to be triggers for breast cancer: the estrogen
receptor, the progesterone receptor, and the human epidermal growth factor receptor. When a
type of cancer has one or more of these receptors, it is considered to be “positive” for that
specific receptor; while on the other hand, if the cancer does not have that receptor then it is
considered to be “negative.” About 10-20% of all breast cancers diagnosed are a form of triple
negative breast cancer (TNBC) because they lack these three pivotal hormone receptors, making
TNBC the most aggressive type due to the high mortality rate. TNBCs exhibit a greater
resistance towards the standard therapeutic procedures, requiring a more intrusive form of radio/chemo-therapies and even multiple surgeries to combat the higher metastatic and reoccurrence
rates, confining the patient to a prolonged time for convalescence. Unfortunately the previously
mentioned therapies are not capable of selectively targeting cancer cells specifically and

decimate both cancerous and healthy cells. The insurmountable side effects (hair loss, organ
damage, possible metastasis, secondary cancers etc.) of the current treatments have lead to an
increase in the collaborative efforts towards finding a new therapy to combat the disease through
the use of more precise agents.
Recent studies regard the over-expression of a particular reverse transcription (RT)
enzyme, Telomerase, as a pivotal indicator of the immortalization in 80%-90% of cancers (2).
Reverse transcriptase enzymes gain most of their notoriety for their crucial role in the
propagation of the HIV epidemic. Although these enzymes are similar and have the same
function, these RT enzymes are not the same. This dual part RT enzyme has a RNA template that
allows it to work in tandem with the catalytic part of the enzyme specific for humans, human
telomerase reverse transcriptase (hTERT), to elongate the protective end-caps (telomeres) of the
chromosomes through the addition of many repeats of the same base pair series TTAGGG.
Telomeres will naturally reduce by approximately 30-120 base pairs with subsequent cycles of
cellular replication with no means of elongation in normal somatic cells. Healthy cells without an
active telomerase expect a set number of population doublings, known as the Hayflick limit,
before entering a state of replicative inactivity known as cellular senescence (3). Without this
growth arrest, a cell would perpetually divide and eventually damage genetic code crucial to the
survival of the cell, thus activating a DNA damage response apoptotic pathway. Therefore,
extension of the telomeres grants an unlimited cellular replication potential in somatic cells
through the evasion of expressing this senescence-like phenotype. Once a cell enters the state of
irreversible cellular senescence, its replicative potential becomes zero even though it is otherwise
a healthy and metabolically active cell. This ground breaking discovery catalyzed the production
of a novel strategy to combat TNBC through the use of novel molecules that effectively target
telomere/telomerase complex, and eventually hinder their proliferation rates (2).
There are two main classes of telomerase inhibitors, each affecting a different site of
function for the telomerase enzyme. One is known as a nucleoside reverse transcriptase inhibitor
(NRTI) which is disguised as a nucleoside base used in transcription which will then disrupt the
replicative chain. The other class is known as non-nucleoside reverse transcriptase inhibitors
(NNRTI) which will non-competitively bind to the telomerase enzyme. One well-documented
synthetic agent known as BIBR1532 belongs to the class of NNRTIs and can effectively bind to

the enzyme, halting the enzymatic activity. The specific inhibitory mechanism of this NNRTI is
not completely understood, though there are two main theories that have become generally
accepted. The first states that BIBR1532 attaches to a binding site near enough to the binding site
for replication that it blocks the replication binding site and thus hindering telomerase; the
second, BIBR1532 causes a conformational change in the structure of the telomerase enzyme
after binding to it which will then block the replication binding site from being active (4).
Essentially both of these compounds directly impede upon the unlimited proliferative capacity of
cancerous cells, slowing their propagation, and eventually stopping the disease’s progress.
A novel analogue of the NNRTI, BIBR1532, called GV6 was developed at Grand Valley
State University and its potential as an anti-tumor/anti-telomerase agent is currently unknown.
Therefore, our goals were to compare the short-term and the long-term anti-proliferative effects
of GV6 on MDA-MB 231 TNBC cells to the previously investigated telomerase inhibitor
BIBR1532, as well as to compare the effectiveness of the two inhibitors on the induction of a
senescence-like phenotype in the cells. Our hypothesis is that the anti-proliferative and
senescence inducing effects of GV6 will parallel that of BIBR1532.

Methods
Cell line
TNBC cells (MDA-MB231) were seeded into T-75 Ventilated Culture Flasks and cultured in
RPMI (Life Technologies, NY) media supplemented with 10% fetal bovine serum (Innovative
Research, MI) plus 100 unit/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml Amphotericin
B (Life Technologies, NY) in an incubator set at 37 °C and 5% CO2.
Treatment
Cells were seeded at a density of 1.00 x 106 cells/ml and left undisturbed for 72 hours in RPMI
control media to allow acclimation to the culture conditions. After the 72 hours had transpired,
the media was aspirated and replaced with fresh RPMI media supplemented with either Solvent
(5% DMSO) alone [control] (n=3), 25µm GV6 (n=4), or 25µm BIBR1532 (n=4).
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Figure 1: The Chemical structure
structures of BIBR1532 (R=COOH). The structure of GV6 is under
intellectual property and therefore its structure has not been shown.
Viability Assessment
At days 5, 9, 14, 18, and 27 of culture in experimental treatments,, relative cell densities were
evaluated using
ng a hemocytometer and the live to dead ratios were calculated using the Trypan
Blue Exclusion Test (Life Technologies, NY). When a cell dies the cellular membrane becomes
more permeable which allows the Trypan Blue Stain to be absorbed into the cell thus staining it
blue. The Number of live/dead cells was estimated by counting and averaging the number of
cells within the set of four defined grids uusing
sing an inverted microscope (Leica IL; 100X)
Senescence Test
A commercially available Senescence
Senescence-Associated β-galactosidase (SA-βGal)
Gal) Staining Kit (Cell
Signaling Technology, MA) was used on days 14 and 27 to detect the cellular activity of βgalactosidase in the lysosomes at slightly acidic pH 6.0. The percentage of SA
SA-β
βGal positive
cells was estimated by counting the number of blue
blue-stained
stained cells in a micrograph obtained using
an inverted microscope (Olympus, PA; 100X)

(i)

(ii)

Figure 2: Micrograph of MDA-MB
MB 231 Cells illustrating (i) cells exhibiting a Senescence-like
Senescence
phenotype (S) and Non-senescence
senescence (Replicatively Active) cells (A) [400X magnification], and
(ii) viable and non-viable
viable cells on one grid of a hemocytometer (Trypan Blue Exclusion Test).

Statistics
Statistical analysis was done using the computer program SPSS (Statistics Version 20, IBM
Corporation NY). Difference of P < 0.05 w
was considered significant.

Results

MB 231 cells, flasks
Figure 3: To determine the effect of the Solvent (DMSO 5%) on the MDA-MB
were seeded at a density of about 1.00 x 106 cells/ml in RPMI media supplemented
lemented with either
Solvent (n=3) or Solvent-free (RPMI alone) (n=3).
After culture for five and nine days
days, assessment of the live/dead ratio was performed
using the Trypan-Blue
lue exclusion test and data are presented as Mean ± SD. At day 5, both trial
flasks exhibited a corresponding cell density of roughly 1.50 x 106 cells/ml. By day 9 the cells
density peaked in both treatments at approximately 2.00 x 106 cells/ml. These results indicate
that the presence of 5% DMSO in the media has no effect on growth kinetics of the MDA-MB
MDA
231 cells. Therefore, the difference noted in cell kinetics during our experimental trials can be
justifiably attributed to the effects of the GV6 and BIBR1532, and not to the presence of 5%
5
DMSO.
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Figure 4: The number
umber of viable MDA
MDA-MB
MB 231 cells in media supplemented with GV6 and
BIBR1532 at days 5, 9, 14, 18, and 27 had been determined using the Trypan-Blue
Blue exclusion test
(n=3). The cell counts are expressed as percents relative to Solvent-Control and data
d are shown
as Mean ± SD. The anti-proliferative
proliferative effects of the compounds are shown to be time dependent.
The ab, ac, ad, ae, and af means within each of the treatment are significantly different (p<0.05) and
means between the treatments at each point a, b, c, d, e, and f are not statistically different (p>0.05).
During the short-term treatment trial
trial, the decrease in the number of viable cells in BIBR1532
(40%) supplemented media was almost double of GV6 (20%) by day 5. However, by day 14,
corresponding growth deficits were noted under both treatments. Long-term
term treatment trials
depicted a comparable drop in number of viable cells at days 9 (~50%), 18 (~45%) and 27
(~30%), relative to Solvent-control
control, respectively. Both, the short-term and long-term
term trials,
trials
indicate that GV6 has an anti-proliferative
proliferative effect that mirrors the overall effect of BIBR1532 on
the TNBC cells. These results parallel the current published literature on small molecule
inhibitor that indicate the effectiveness of BIBR1532 as a telomerase inhibitor
inhibitor, as well as
demonstrate a similar negative effect on the growth kinetics of the MDA-MB
MB 231 cells, dropping
to nearly 25% of the proliferation rates of the control cells at concentration of 25µM.
25µ (2) The
next step would be to compare and contrast the dose-dependent curves of BIBR1532 and GV6
and validate whether it corresponds
rresponds to published results.

Figure 5: Number of dead MDA
MDA-MB 231 cellss in media supplemented with GV6
GV and BIBR1532
at days 5, 9, 14, 18, and 27 in comparison to Solvent-Control
ontrol as determined by Trypan-Blue
Trypan
exclusion test (n=3-5).
5). Data are shown as Mean ±
±SD.
The amount of dead cells was approximately 5% of the normal live-cell rate of Solvent-control
S
(2.00 x 106 cells/ml) and fluctuated only a negligible amount throughout the trials. This means
that GV6 and BIBR1532 do not ccause an increase in the rate of cell death but, instead,
instead only slow
the proliferation rate of the cells..
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Figure 6: Number of (A) senescent cells/treatment in comparison to Control (Solvent), and (B)
non-senescent (replicatively active) cells on days 14 and 27 of treatment. Data are shown as
Mean ± SD. ab, ac, ad, and ae, means within each panel are significantly different (p<0.05).
The time dependent increase in the number of cells expressing a senescence-like phenotype is
equivalent for GV6 and BIBR1532. By day 14, GV6 and BIBR1532 supplemented flasks have
approximately double the number of senescent cells in comparison to Solvent-control and the
number of replicatively active cells corresponds between the two treatments. A three-fold
increase in the number of senescent cells and a nearly 70% reduction in the number of active
cells was observed for both treatments by day 27.

Conclusion and Future Projects
This study illustrates that the anti-proliferation effect of GV6 is as potent as BIBR1532 in
inhibiting rates of triple-negative breast cancer cells both in the short- and long-term setting. The
ability of GV6 to effectively induce a senescence-like phenotype in treated cells has also been
observed. Further studies include using real time PCR to determine the level of relative gene
expression in treatment supplemented cells as opposed to solvent supplemented cells and
quantifying the levels of telomerase expression in the cells.
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